Pharmacologic therapeutics for cardiac reperfusion injury

Expert Opinion on Emerging Drugs

Volumn 12, Issue 3, 2007, Pages 367-388

  Gross, Eric R ^a   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adenosine; Akt; Bradykinin; Channel; Delayed preconditioning; Dose; ERK; Glucose insulin potassium; Glycogen synthase kinase; HMG Co A reductase; Infarct size; Ischemia; KATP; Mitochondrial permeability transition pore; Morphine; MPTP; Na H exchanger; Opioid; PDE; PI3k; PKC; Postconditioning; PPAR; Preconditioning; Reperfusion; RISK; Statin; Window

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 HYDROXYBENZYL] N,N DIETHYLBENZAMIDE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ARD 353; BRADYKININ; DELTA OPIATE RECEPTOR AGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INHALATION ANESTHETIC AGENT; INSULIN; ION CHANNEL; MEMBRANE RECEPTOR; MORPHINE; OPIATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; TRANSCRIPTION FACTOR; TRIMETAZIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CARDIOVASCULAR AGENT; CARRIER PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PROTEIN KINASE INHIBITOR;

ALLERGIC REACTION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; HEART INFARCTION; HEART INJURY; HEART MUSCLE CELL; HUMAN; HYPERTENSION; MITOCHONDRIAL PERMEABILITY; MORBIDITY; MORTALITY; NAUSEA; PROTEIN TARGETING; REPERFUSION INJURY; REVIEW; SIDE EFFECT; THROMBOSIS; VOMITING; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; HEART MITOCHONDRION; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG DESIGN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 34748918902     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.3.367     Document Type: Review

References (122)

1. ROSAMOND W, FLEGAL K, FRIDAY G et al.: Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2007) 115:E69-E171.
2. MINING AM, HERON MP, SMITH BL: Deaths: preliminary data for 2004. Natl. Vital. Stat. Ref. (2006) 54:1-49.
3. DEFRANCES CJ, PODGORNIK MN: 2004 National Hospital Discharge Survey. Adv. Data (2006):1-19.
4. HING E, CHERRY DK, WOODWELL DA: National Ambulatory Medical Care Survey: 2004 summary. Adv. Data (2006):1-33.
5. MURRY CE, JENNINGS RB, REIMER KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation (1986) 74:1124-1136.
6. ZHAO ZQ, CORVERA JS, HALKOS ME et al.: Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol. (2003) 285:H579-H588.
7. MCGINN AP, ROSAMOND WD, GOFF DC Jr, TAYLOR HA, MILES JS, CHAMBLESS L: Trends in prehospital delay time and use of emergency medical services for acute myocardial infarction: experience in 4 US communities from 1987 - 2000. Am. Heart J. (2005) 150:392-400.
8. KLONER RA: Does reperfusion injury exist in humans? J. Am. Coll. Cardiol. (1993) 21:537-545.
9. + channel. J. Mol. Cell Cardiol. (1997) 29:175-182.
10. MAHAFFEY KW, PUMA JA, BARBAGELATA NA et al.: Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J. Am. Coll. Cardiol. (1999) 34:1711-1720.
11. ROSS AM, GIBBONS RJ, STONE GW, KLONER RA, ALEXANDER RW: A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol. (2005) 45:1775-1780.
12. KLONER RA, FORMAN MB, GIBBONS RJ, ROSS AM, ALEXANDER RW, STONE GW: Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur. Heart J. (2006) 27:2400-2405.
13. GROSS GJ, AUCHAMPACH JA: Reperfusion injury: does it exist? J. Mol. Cell Cardiol. (2007) 42:12-18.
14. NORTON ED, JACKSON EK, TURNER MB, VIRMANI R, FORMAN MB: The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury. Am. Heart J. (1992) 123:332-338.
15. XU Z, DOWNEY JM, COHEN MV: AMP579 reduces contracture and limits infarction in rabbit heart by activating adenosine A2 receptors. J. Cardiovasc. Pharmacol. (2001) 38:474-481.
16. PITARYS CJ II, VIRMANI R, VILDIBILL HD Jr, JACKSON EK, FORMAN MB: Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation (1991) 83:237-247.
17. VELASCO CE, TURNER M, COBB MA, VIRMANI R, FORMAN MB: Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine. Am. Heart J. (1991) 122:1561-1570.
18. LOUTTIT JB, HUNT AA, MAXWELL MP, DREW GM: The time course of cardioprotection induced by GR79236, a selective adenosine A1-receptor agonist, in myocardial ischaemia-reperfusion injury in the pig. J. Cardiovasc. Pharmacol. (1999) 33:285-291.
19. SMITS GJ, MCVEY M, COX BF, PERRONE MH, CLARK KL: Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J. Pharmacol. Exp. Ther. (1998) 286:611-618.
20. BAXTER GF, HALE SL, MIKIT et al.: Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc. Drugs Ther. (2000) 14:607-614.
21. YANG XM, KRIEG T, CUI L, DOWNEY JM, COHEN MV: NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PBK, ERK, and NO. J. Mol. Cell Cardiol. (2004) 36:411-421.
22. FORSTER K, PAUL I, SOLENKOVA N et al.: NECA at reperfusion limits infarction and inhibits formation of the mitochondrial permeability transition pore by activating p70S6 kinase. Basic Res. Cardiol. (2006) 101:319-326.
23. XU Z, DOWNEY JM, COHEN MV: Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart. Heart Dis. (2003) 5:368-371.
24. KIS A, BAXTER GF, YELLON DM: Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2. Cardiovasc. Drugs Ther. (2003) 17:415-425.
25. LASLEY RD, JAHANIA MS, MENTZER RM Jr: Beneficial effects of adenosine A(2a) agonist CGS-21680 in infarcted and stunned porcine myocardium. Am. J. Physiol. Heart Circ. Physiol. (2001) 280:H1660-H1666.
26. JORDAN JE, ZHAO ZQ, SATO H, TAFT S, VINTEN-JOHANSEN J: Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J. Pharmacol. Exp. Ther. (1997) 280:301-309.
27. MADDOCK HL, MOCANU MM, YELLON DM: Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am. J. Physiol. Heart Circ. Physiol. (2002) 283:H1307-H1313.
28. PARK SS, ZHAO H, JANG Y, MUELLER RA, XU Z: N6-(3-iodobenzyl)- adenosine-5́-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3β. J. Pharmacol. Exp. Ther. (2006) 318:124-131.
29. SCHULTZ JE, HSU AK, GROSS GJ: Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ. Res. (1996) 78:1100-1104.
30. MARMOR M, PENN A, WIDMER K, LEVIN RI, MASLANSKY R: Coronary artery disease and opioid use. Am. J. Cardiol. (2004) 93:1295-1297.
31. MURPHY GS, SZOKOL JW, MARYMONT JH, AVRAM MJ, VENDER JS: Opioids and cardioprotection: the impact of morphine and fentanyl on recovery of ventricular function after cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. (2006) 20:493-502.
32. MEINE TJ, ROE MT, CHEN AY et al.: Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am. Heart J. (2005) 149:1043-1049.
33. WITTERT G, HOPE P, PYLE D: Tissue distribution of opioid receptor gene expression in the rat. Biochem. Biophys. Res. Commun. (1996) 218:877-881.
34. BELL SP, SACK MN, PATEL A, OPIE LH, YELLON DM: Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J. Am. Coll. Cardiol. (2000) 36:2296-2302.
35. GROSS ER, GROSS GJ: Ligand triggers of classical preconditioning and postconditioning. Cardiovasc. Res. (2006) 70:212-221.
36. GROSS ER, HSU AK, GROSS GJ: Opioid-induced cardioprotection occurs via glycogen synthase kinase beta inhibition during reperfusion in intact rat hearts. Circ. Res. (2004) 94:960-966.
37. ATP channel opening mediate acute opioid-induced cardioprotection at reperfusion. Basic Res. Cardiol. (2007) [Epub ahead of print].
38. GROSS ER, PEART JN, HSU AK, AUCHAMPACH JA, GROSS GJ: Extending the cardioprotective window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. Am. J. Physiol. Heart Circ. Physiol. (2005) 288:H2744-H2749.
39. WATSON MJ, HOLT JD, O'NEILL SJ et al.: ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyi)methyl)-2, 5-dimethylpiperazin-1-ylmethyl)benzoic acid], a novel nonpeptide delta receptor agonist, reduces myocardial infarct size without central effects. J. Pharmacol. Exp. Ther. (2006) 316:423-430.
40. PARRATT JR, VEGH A, PAPP JG: Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning - a brief review of the evidence. Can. J. Physiol. Pharmacol. (1995) 73:837-842.
41. LEESAR MA, STODDARD MF, MANCHIKALAPUDI S, BOLLI R: Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. J. Am. Coll. Cardiol. (1999) 34:639-650.
42. HORNIG B, KOHLER C, DREXLER H: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation (1997) 95:1115-1118.
43. TOKMAKOVA M, SOLOMON SD: Inhibiting die renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Curr. Opin. Cardiol. (2006) 21:268-272.
44. YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES R, DAGENAIS G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. (2000) 342:145-153.
45. BAXTER GF, EBRAHIM Z: Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Br. J. Pharmacol. (2002) 135:843-854.
46. HARTMAN JC, HULLINGER TG, WALL TM, SHEBUSKI RJ: Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur. J. Pharmacol. (1993) 234:229-236.
47. TSCHOPE C, HERINGER-WALTHER S, KOCH M et al.: Upregulation of bradykinin B1-receptor expression after myocardial infarction. Br. J. Pharmacol. (2000) 129:1537-1538.
48. BELL RM, YELLON DM: Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PBK, Akt and eNOS. J. Mol. Cell Cardiol. (2003) 35:185-193.
49. PARK SS, ZHAO H, MUELLER RA, XU Z: Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3β. J. Mol. Cell Cardiol. (2006) 40:708-716.
50. NAMIUCHI S, KAGAYA Y, OHTA J et al.: High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J. Am. Coll. Cardiol. (2005) 45:1406-1412.
51. SINGH AK, SZCZECH L, TANG KL et al.: Correction of anemia with epoetin alpha in chronic kidney disease. N. Engl. J. Med. (2006) 355:2085-2098.
52. LIPSIC E, VAN DER MEER P, VOORS AA et al.: A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc. Drugs Ther. (2006) 20:135-141.
53. LIPSIC E, VAN DER MEER P, HENNING RH: Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J. Cardiovasc. Pharmacol. (2004) 44:473-479.
54. PRUNIER F, PFISTER O, HADRI L et al.: Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am. J. Physiol. Heart Oirc. Physiol. (2007) 292:H522-H229.
55. LIPSIC E, SCHOEMAKER RG, VAN DER MEER P, VOORS AA, VAN VELDHUISEN DJ, VAN GILST WH: Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J. Am. Coll. Cardiol. (2006) 48:2161-2167.
56. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; A double-blind, placebo-controlled, randomized trial. The EMIP-FR group. European myocardial infarction project - free radicals. Eur. Heart. J. (2000) 21:1537-1546.
57. VAN DER HORST IC, ZIJLSTRA F, VAN'T HOF AW et al.: Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J. Am. Coll. Cardiol. (2003) 42:784-791.
58. RASOUL S, OTTERVANGER JP, TIMMER JR et al.: One year outcomes after glucose-insulin-potassium in ST elevation myocardial infarction. The Glucose-insulin-potassium study II. Int. J. Cardiol. (2007) [Epub ahead of print].
59. MEHTA SR, YUSUF S, DIAZ R et al.: Effect of glucose-insulin- potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 293:437-446.
60. MALMBERG K: Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ (1997) 314:1512-1515.
61. MALMBERG K, RYDEN L, EFENDIC S et al.: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J. Am. Coll. Cardiol. (1995) 26:57-65.
62. MALMBERG K, RYDEN L, WEDEL H et al.: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur. Heart J. (2005) 26:650-661.
63. JONASSEN AK, AASUM E, RIEMERSMA RA, MJOS OD, LARSEN TS: Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc. Drugs Ther. (2000) 14:615-623.
64. ATP channel opening and blood glucose concentration before ischemia. Am. J. Physiol. Heart Ore. Physiol. (2004) 287:H601-H607.
65. JONASSEN AK, SACK MN, MJOS OD, YELLON DM: Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ. Res. (2001) 89:1191-1198.
66. SCHLACK W, HOLLMANN M, STUNNECK J, THAMER V: Effect of halothane on myocardial reoxygenation injury in the isolated rat heart. Br. J. Anaesth. (1996) 76:860-867.
67. NADER ND, LI CM, KHADRA WZ, REEDY R, PANOS AL: Anesthetic myocardial protection with sevoflurane. J. Cardiothorac. Vasc. Anesth. (2004) 18:269-274.
68. DE HERT SG, VAN DER LINDEN PJ, CROMHEECKE S et al.: Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration. Anesthesiology (2004) 101:299-310.
69. SYMONS JA, MYLES PS: Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br. J. Anaesth. (2006) 97:127-136.
70. WEIHRAUCH D, KROLIKOWSKI JG, BIENENGRAEBER M, KERSTEN JR, WARLTIER DC, PAGEL PS: Morphine enhances isoflurane-induced postconditioning against myocardial infarction: the role of phosphatidylinositol-3-kinase and opioid receptors in rabbits. Anesth. Analg. (2005) 101:942-949.
71. PRATT PF Jr, WANG C, WEIHRAUCH D et al.: Cardioprotection by volatile anesthetics: new applications for old drugs? Curr. Opin. Anaesthesiol. (2006) 19:397-403.
72. KEECH A, SIMES RJ, BARTER P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 366:1849-1861.
73. DORMANDY JA, CHARBONNEL B, ECKLAND DJ et al.: Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet (2005) 366:1279-1289.
74. NISSEN SE, WOLSKI K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) [Epub ahead of print].
75. MURRIEL CL, MOCHLY-ROSEN D: Opposing roles of delta and epsilonPKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Arch. Biochem. Biophys. (2003) 420:246-254.
76. INAGAKI K, HAHN HS, DORN GW II, MOCHLY-ROSEN D: Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator. Circulation (2003) 108:869-875.
77. KUKREJA RC, SALLOUM F, DAS A et al.: Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul. Pharmacol. (2005) 42:219-232.
78. SALLOUM FN, OCKAILI RA, WITTKAMP M, MARWAHAVR, KUKREJA RC: Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. J. Mol. Cell Cardiol. (2006) 40:405-411.
79. SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 285:1711-1718.
80. FONAROW GC, WRIGHT RS, SPENCER FA et al.: Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am. J. Cardiol. (2005) 96:611-616.
81. HERRMANN J, LERMAN A, BAUMGART D. et al.: Preprocedural statin medication reduces the extent of periprocedural non-q-wave myocardial infarction. Circulation (2002) 106:2180-2183.
82. PASCERI V, PATTI G, NUSCA A, PRISTIPINO C, RICHICHI G, DI SCIASCIO G: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasry) study. Circulation (2004) 110:674-678.
83. NAKAYA R, UZUI H, SHIMIZU H et al.: Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int. J. Cardiol. (2005) 105:67-73.
84. CHELLO M, CARASSITI M, AGRO F et al.: Simvastatin blunts the increase of circulating adhesion molecules after coronary artery bypass surgery with cardiopulmonary bypass. J. Cardiothorac. Vasc. Anesth. (2004) 18:605-609.
85. JONES SP, TROCHA SD, LEFER DJ: Pretreatment with simvastatin attenuates myocardial dysfunction after ischemia and chronic reperfusion. Arterioscler. Thromb. Vasc. Biol. (2001) 21:2059-2064.
86. BELL RM, YELLON DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J. Am. Coll. Cardiol. (2003) 41:508-515.
87. WOLFRUM S, DENDORFER A, SCHUTT M et al.: Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J. Cardiovasc. Pharmacol. (2004) 44:348-355.
88. WRIGHT DG, LEFER DJ: Statin mediated protection of the ischemic myocardium. Vascul. Pharmacol. (2005) 42:265-270.
89. ITO H, TANIYAMA Y, IWAKURA K et al.: Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J. Am. Coll. Cardiol. (1999) 33:654-660.
90. OTA S, NISHIKAWA H, TAKEUCHI M et al.: Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ. J. (2006) 70:1099-1104.
91. ATP channels and myocardial preconditioning: an update. Am. J. Physiol. Heart Circ. Physiol. (2003) 285:H921-H930.
92. ZEYMER U, SURYAPRANATA H, MONASSIERJP et al.: The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J. Am. Coll. Cardiol. (2001) 38:1644-1650.
93. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet (2002) 360:1189-1196.
94. Hyaluronidase therapy for acute myocardial infarction: results of a randomized, blinded, multicenter trial. MILIS Study Group. Am. J. Cardiol. (1986) 57:1236-1243.
95. FLAHERTY JT, PITT B, GRUBER JW et al.: Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation (1994) 89:1982-1991.
96. WALL TC, CALIFF RM, BLANKENSHIP J et al.: Intravenous fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. Circulation (1994) 90:114-120.
97. BARAN KW, NGUYEN M, MCKENDALL GR et al.: Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation (2001) 104:2778-2783.
98. FAXON DP, GIBBONS RJ, CHRONOS NA, GURBEL PA, SHEEHAN F: The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J. Am. Coll. Cardiol. (2002) 40:1199-1204.
99. LEESAR MA, STODDARD MF, DAWN B, JASTI VG, MASDEN R, BOLLI R: Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation (2001) 103:2935-2941.
100. MOON C, KRAWCZYK M, PAIK D, LAKATTA EG, TALAN MI: Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window. Cardiovasc. Drugs Ther. (2005) 19:243-250.
101. TONG H, IMAHASHI K, STEENBERGEN C, MURPHY E: Phosphorylation of glycogen synthase kinase-3β during preconditioning through a phosphatidylinositol-3- kinase-dependent pathway is cardioprotective. Circ. Res. (2002) 90:377-379.
102. PAGEL PS, KROLIKOWSKIJG, NEFF DA et al.: Inhibition of glycogen synthase kinase enhances isoflurane-induced protection against myocardial infarction during early reperfusion in vivo. Anesth. Analg. (2006) 102:1348-1354.
103. FENG J, LUCCHINETTI E, AHUJA P, PASCH T, PERRIARD JC, ZAUGG M: Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3β. Anesthesiology (2005) 103:987-995.
104. KOSTYAK JC, HUNTER JC, KORZICK DH: Acute PKCδ inhibition limits ischaemia-reperfusion injury in the aged rat heart: rale of GSK-3β. Cardiovasc. Res. (2006) 70:325-334.
105. GROSS ER, HSU AK, GROSS GJ: Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3β. Diabetes (2007) 56:127-136.
106. HAUSENLOY DJ, MADDOCK HL, BAXTER GF, YELLON DM: Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc. Res. (2002) 55:534-543.
107. WANG C, NEFF DA, KROLIKOWSKI JG et al.: The influence of B-cell lymphoma 2 protein, an antiapoptotic regulator of mitochondrial permeability transition, on isoflurane-induced and ischemic postconditioning in rabbits. Anesth. Analg. (2006) 102:1355-1360.
108. ATP channels. Anesth. Analg. (2005) 101:1590-1596.
109. ARGAUD L, GATEAU-ROESCH O, RAISKY O, LOUFOUAT J, ROBERT D, OVIZE M: Postconditioning inhibits mitochondrial permeability transition. Circulation (2005) 111:194-197.
110. JUHASZOVA M, ZOROV DB, KIM SH et al.: Glycogen synthase kinase-3β mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J. Clin. Invest. (2004) 113:1535-1549.
111. LEMMON MA, FERGUSON KM: Molecular determinants in pleckstrin homology domains that allow specific recognition of phosphoinositides. Biochem. Soc. Trans. (2001) 29:377-384.
112. VANHAESEBROECK B, ALESSI DR: The PI3K-PDK1 connection: more than just a road to PKB. Biochem. J. (2000) 346 (Part 3):561-576.
113. DOUKAS J, WRASIDLO W, NORONHA G et al.: Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc. Natl. Acad. Sci. USA (2006) 103:19866-19871.
114. DING Q, XIA W, LIU JC et al.: Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of β-catenin. Mol. Cell (2005) 19:159-170.
115. FRAME S, COHEN P: GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. (2001) 359:1-16.
116. HOSHI M, SATO M, KONDO S et al.: Different localization of tau protein kinase I/glycogen synthase kinase-3β from glycogen synthase kinase-3α in cerebellum mitochondria. J. Biochem. (Tokyo) (1995) 118:683-685.
117. GATEAU-ROESCH O, ARGAUD L, OVIZE M: Mitochondrial permeability transition pore and postconditioning. Cardiovasc. Res. (2006) 70:264-273.
118. GROSS ER, HSU AK, GROSS GJ: Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. J. Pharmacol. Exp. Ther. (2004) 310:185-191.
119. LANGE M, SMUL TM, BLOMEYER CA et al.: Role of the β1-adrenergic pathway in anesthetic and ischemic preconditioning against myocardial infarction in the rabbit heart in vivo. Anesthesiology (2006) 105:503-510.
120. PEART JN, GROSS GJ: Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways. Am. J. Physiol. Heart Circ. Physiol. (2006) 291:H1746-H1753.
121. SCHWARTZ GG, OLSSON AG, SZAREK M, SASIELA WJ: Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) trial. Diabetes Care (2005) 28:2508-2513.
122. ATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with Type 2 diabetes. Diabetes (2003) 52:568-572.